Head-To-Head Survey: Protagenic Therapeutics (PTIX) vs. Its Competitors

Protagenic Therapeutics (NASDAQ:PTIX) is one of 1,000 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Protagenic Therapeutics to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Protagenic Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protagenic Therapeutics	N/A	-$5.00 million	-1.11
Protagenic Therapeutics Competitors	$2.02 billion	$147.25 million	-1.33

Protagenic Therapeutics’ peers have higher revenue and earnings than Protagenic Therapeutics. Protagenic Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for Protagenic Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagenic Therapeutics	0	0	0	0	N/A
Protagenic Therapeutics Competitors	6384	18714	44577	917	2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 84.65%. Given Protagenic Therapeutics’ peers higher probable upside, analysts plainly believe Protagenic Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Protagenic Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagenic Therapeutics	N/A	-101.81%	-82.18%
Protagenic Therapeutics Competitors	-2,458.79%	-294.93%	-30.61%

Volatility & Risk

Protagenic Therapeutics has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics’ peers have a beta of 1.12, indicating that their average stock price is 12% more volatile than the S&P 500.

Summary

Protagenic Therapeutics peers beat Protagenic Therapeutics on 6 of the 10 factors compared.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.